Aiming to transform treatment of cancer and autoimmune and inflammatory diseases by developing allogeneic, iPSC-derived NK and T cell therapies.
PRESS RELEASES + EVENTS view all
Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
PHILADELPHIA, Nov. 21, 2023 (GLOBE NEWSWIRE) — Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company…
Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
– Brent Pfeiffenberger, Pharm.D., MBA, appointed Chief Executive Officer of Century Therapeutics – – Initial…
We are building an industry leading allogeneic iPSC-derived cell therapy platform for cancer and autoimmune and inflammatory diseases.
We are leveraging the unlimited self-renewing capacity of induced pluripotent stem cells (iPSC) and cutting-edge cellular engineering and manufacturing technologies to develop fit-for-purpose products with functionalities designed to overcome the limitations of existing cell therapies.